BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9661877)

  • 21. Engineered CD8+ cytotoxic T cells with fiber-modified adenovirus-mediated TNF-alpha gene transfection counteract immunosuppressive interleukin-10-secreting lung metastasis and solid tumors.
    Ye Z; Shi M; Chan T; Sas S; Xu S; Xiang J
    Cancer Gene Ther; 2007 Jul; 14(7):661-75. PubMed ID: 17479109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth inhibition of transplantable tumors in mice by mIL-2-secreting murine plasmocytoma cells used alone or in combination with a cytostatic agent.
    Pajtasz-Piasecka E; Kuśnierczyk H; Salwa J; Konarski L; Radzikowski C
    Arch Immunol Ther Exp (Warsz); 1995; 43(5-6):281-92. PubMed ID: 8744648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors.
    Helguera G; Dela Cruz JS; Lowe C; Ng PP; Trinh R; Morrison SL; Penichet ML
    Vaccine; 2006 Jan; 24(3):304-16. PubMed ID: 16125282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficient growth inhibition of ErbB2-overexpressing tumor cells by anti-ErbB2 ScFv-Fc-IL-2 fusion protein in vitro and in vivo.
    Shi M; Zhang L; Gu HT; Jiang FQ; Qian L; Yu M; Chen GJ; Luo Q; Shen BF; Guo N
    Acta Pharmacol Sin; 2007 Oct; 28(10):1611-20. PubMed ID: 17883948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of established tumor growth in syngeneic mice by local inoculation of engineered mouse myeloma cells secreting a recombinant fusion protein RM4/TNF.
    Xiang J; Qi Y; Chen Y
    Cancer Gene Ther; 1997; 4(6):353-8. PubMed ID: 9408605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
    Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
    Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
    Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
    J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of immunity in peripheral tissues combined with intracerebral transplantation of interleukin-2-producing cells eliminates established brain tumors.
    Iwadate Y; Yamaura A; Sato Y; Sakiyama S; Tagawa M
    Cancer Res; 2001 Dec; 61(24):8769-74. PubMed ID: 11751397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of antitumor immunity by combined immunogene therapy using IL-2 and IL-12 in low antigenic Lewis lung carcinoma.
    Tanaka M; Saijo Y; Sato G; Suzuki T; Tazawa R; Satoh K; Nukiwa T
    Cancer Gene Ther; 2000 Nov; 7(11):1481-90. PubMed ID: 11129290
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intratumoral injection of IL-secreting syngeneic/allogeneic fibroblasts transfected with DNA from breast cancer cells prolongs the survival of mice with intracerebral breast cancer.
    Lichtor T; Glick RP; Lin H; O-Sullivan I; Cohen EP
    Cancer Gene Ther; 2005 Aug; 12(8):708-14. PubMed ID: 15803143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insertion of the IL-2 gene decreases tumorigenicity of murine fibrosarcoma.
    Kuśnierczyk H; Załecki P; Pajtasz-Piasecka E; Radzikowski C
    Arch Immunol Ther Exp (Warsz); 1998; 46(4):259-65. PubMed ID: 9779293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suppression of cell-mediated and humoral immune responses by an interleukin-2-immunoglobulin fusion protein in mice.
    Kunzendorf U; Pohl T; Bulfone-Paus S; Krause H; Notter M; Onu A; Walz G; Diamantstein T
    J Clin Invest; 1996 Mar; 97(5):1204-10. PubMed ID: 8636431
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eosinophils infiltrating interleukin-5 gene-transfected tumors do not suppress tumor growth.
    Krüger-Krasagakes S; Li W; Richter G; Diamantstein T; Blankenstein T
    Eur J Immunol; 1993 Apr; 23(4):992-5. PubMed ID: 8458388
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors.
    Sampath P; Hanes J; DiMeco F; Tyler BM; Brat D; Pardoll DM; Brem H
    Cancer Res; 1999 May; 59(9):2107-14. PubMed ID: 10232596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Induction of Th1 immune response against tumor by genetically engineered fusion of tumor cells and dendritic cells].
    Zhang W; Yang H; Zeng H; Chen Z
    Zhonghua Xue Ye Xue Za Zhi; 2002 Feb; 23(2):61-4. PubMed ID: 12015071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
    Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
    Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of GM-CSF and IL-2 co-expression on the anti-tumor immune response.
    Lee SG; Heo DS; Yoon SJ; Jee YS; Kang JO; Kim K; Kim CD; Sung MW; Kim NK
    Anticancer Res; 2000; 20(4):2681-6. PubMed ID: 10953343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration.
    Hara I; Nagai H; Miyake H; Yamanaka K; Hara S; Micallef MJ; Kurimoto M; Gohji K; Arakawa S; Ichihashi M; Kamidono S
    Cancer Gene Ther; 2000 Jan; 7(1):83-90. PubMed ID: 10678360
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer.
    Reinartz S; Hombach A; Köhler S; Schlebusch H; Wallwiener D; Abken H; Wagner U
    Cancer Res; 2003 Jun; 63(12):3234-40. PubMed ID: 12810653
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
    Douin-Echinard V; Bornes S; Rochaix P; Tilkin AF; Peron JM; Bonnet J; Favre G; Couderc B
    Cancer Gene Ther; 2000 Dec; 7(12):1543-56. PubMed ID: 11228533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.